Halia Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ofirnoflast (HT-6184) for the treatment of adults with lower-risk myelodysplastic syndromes (LR-MDS).
The designation marks an important step for the company as it continues the development of its lead investigational therapy for patients who have limited treatment options and often struggle with chronic anemia and transfusion dependence.
Fast Track designation is designed to help speed up the development and regulatory review of therapies intended to treat serious conditions where there is a significant unmet medical need.
With this designation, Halia Therapeutics may benefit from more frequent interactions with the FDA and could become eligible for programs such as Accelerated Approval, Priority Review, and Rolling Review if the required criteria are met.
According to the company, the designation follows encouraging results from a Phase 2 clinical study evaluating ofirnoflast in patients with lower-risk MDS.
David J. Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, said the designation highlights the ongoing need for new treatment options in lower-risk MDS and provides an opportunity to work closely with regulators as the program advances into later-stage development.
The Phase 2 study was an open-label, single-arm clinical trial involving 37 adult patients with lower-risk MDS.
Participants had symptomatic anemia or were dependent on red blood cell transfusions and were either refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents (ESAs).
Patients received oral ofirnoflast at a dose of 2 mg once daily following a five-days-on, two-days-off treatment schedule for up to 32 weeks.
The primary goal of the study was to evaluate hematologic improvement according to International Working Group (IWG) 2018 criteria.
Among 30 evaluable patients, ofirnoflast achieved an overall best on-study hematologic improvement rate of 67%.
The treatment demonstrated activity across multiple blood cell lineages, including improvements in red blood cells, platelets, and neutrophils.
One of the key findings from the study involved patients who relied on regular blood transfusions.
Among 18 transfusion-dependent participants, 10 patients achieved red blood cell transfusion independence for at least eight weeks.
The median duration of transfusion independence was 28 weeks.
Several patients maintained this benefit for 16 weeks or longer.
For patients who were not dependent on transfusions, the results were also encouraging. Nine out of 12 patients achieved meaningful improvements in red blood cell production.
Researchers also reported a median peak hemoglobin increase of 4.6 g/dL among responding patients.
Safety Profile Supports Continued Development
The study showed that ofirnoflast was generally well tolerated.
No treatment-related serious adverse events were reported during the trial.
Most treatment-related side effects were mild to moderate in severity and occurred in approximately 27% of patients.
Only a small number of patients experienced Grade 3 or higher treatment-related adverse events.
Researchers also observed clinical activity regardless of genetic mutation status, including patients with and without SF3B1 mutations or chromosome 5q deletions.
The treatment demonstrated activity across different World Health Organization (WHO) MDS subtypes.
How Ofirnoflast Works
Ofirnoflast is a first-in-class oral therapy designed to target the NLRP3 inflammasome, a key driver of inflammation and immune signaling.
The drug works by modulating NEK7, a protein involved in inflammasome activation.
In lower-risk MDS, activation of the NLRP3 inflammasome contributes to ineffective blood cell production, bone marrow dysfunction, and anemia.
By preventing inflammasome formation and promoting its disassembly, ofirnoflast aims to address an underlying cause of the disease rather than simply managing symptoms.
Halia Plans Next Stage of Development
Following the positive Phase 2 findings and FDA Fast Track designation, Halia Therapeutics is preparing the next phase of clinical development for ofirnoflast in lower-risk MDS.
Han Myint, M.D., Chief Medical Officer of Halia Therapeutics, said lower-risk MDS continues to represent a major unmet medical need, especially for patients who have exhausted currently available therapies.
The company plans to continue working closely with the FDA as it advances the program toward pivotal development.
Understanding Lower-Risk Myelodysplastic Syndromes
Myelodysplastic syndromes are a group of bone marrow disorders that affect the body's ability to produce healthy blood cells.
Patients often experience chronic anemia, fatigue, increased infection risk, and bleeding complications.
In some cases, the disease can progress to acute myeloid leukemia (AML).
For many patients with lower-risk MDS, repeated blood transfusions become necessary, creating a significant burden on daily life and long-term healthcare management.
About Halia Therapeutics
Halia Therapeutics is a clinical-stage biotechnology company based in Lehi, Utah.
The company focuses on developing first-in-class therapies that target inflammasome-driven diseases through novel mechanisms designed to address the root causes of inflammation-related disorders.
Its lead investigational therapy, ofirnoflast, is currently being developed for lower-risk myelodysplastic syndromes and other hematologic diseases linked to NLRP3 inflammasome biology. The company’s broader pipeline is built around precision medicine and insights from human genetic resilience.